NDRG2 and meningioma: NDRG2 promoter CpG island methylation and down-regulation have been observed in breast,[19] colon,[20] and lung cancer cell lines[19] as well as primary glioblastomas[21] and meningiomas,[22] liver,[23] and colorectal cancer (CRC).[20] Hence, NDRG2 will be a promising molecular target for cancer therapy that could be modulated by novel iron chelators.